Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 2, 2012, Pages 293-303

  Mardjuadi, Feby ^a   Medioni, Jacques ^b,c   Kerger, Joseph ^d   D'Hondt, Lionel ^d   Canon, Jean Luc ^e   Duck, Lionel ^f   Musuamba, Flora ^g   Oudard, Stephane ^b   Clausse, Marylene ^h   Moxhon, Anne ^a   Machiels, Jean Pascal ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSTITUT CURIE   (France)

^d UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^e Department of Hematology Oncology   (Belgium)

^f Clinique Saint Pierre of Ottignies   (Belgium)

^g UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^h Oncology Hematology Unit   (Belgium)

Author keywords

Docetaxel; Metastatic; Pharmacokinetic; Phase 1; Prostate; Sorafenib

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SORAFENIB;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DIARRHEA; DISEASE ASSOCIATION; DOSE LIMITING TOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOCALCEMIA; INFECTION; MAINTENANCE CHEMOTHERAPY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXICOLOGICAL PARAMETERS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PILOT PROJECTS; PREDNISONE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; PYRIDINES; TAXOIDS; TESTOSTERONE;

EID: 84866545393     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1914-y     Document Type: Article

References (44)

1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781
2. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
3. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
4. De Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154
5. De Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
6. Scher HI, Fizazi K, Saad F et al (2012) Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer post docetaxel: Results from the phase III AFFIRM study. Genitourinary cancers symposium. J Clin Oncol 30:Suppl 5 (abstr LBA1)
7. Parker C, Heinrich D, O'Sullivan JM et al (2011) Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): A phase III randomized trial (ALSYMPCA). Eur J Cancer 47(Suppl 2):3
8. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422
9. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW, Cancer and Leukemia Group B 9480 Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7:1932-1936
10. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279-284
11. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140
12. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134
13. Llovet JM, Ricci S, Mazzafero V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
14. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
15. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972
16. Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L (2008) A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19:746-751
17. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD (2008) A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14:209-214
18. Tesei A, Leonetti C, Zupi G, Scarsella M, Brigliadori G, Ulivi P, Fabbri F, Arienti C, Amadori D, Passardi A, Silvestrini R, Zoli W (2011) Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. J Cell Mol Med 15:316-326
19. Ulivi P, Arienti C, Zoli W, Scarsella M, Carloni S, Fabbri F, Tesei A, Chiadini E, Orlandi A, Passeri D, Zupi G, Milandri C, Silvestrini R, Amadori D, Leonetti C (2010) In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. Curr Cancer Drug Targ 10:600-610
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
21. Bubley GJ, Carducci M, Dahut W et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the PSA working group. J Clin Oncol 17:3461-3467
22. Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S (2003) Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma. A phase I and pharmacokinetic study. Cancer 9:1855-1862
23. Verweij J (2008) 'No risk, no fun': Challenges for the oncology phase I clinical trial time-performance. Eur J Cancer 44:2600-2607
24. Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L (2010) Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: A report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 16:1726-1736
25. Zhao M, Rudek MA, He P, Hafner FT, Radtke M, Wright JJ, Smith BD, Messersmith WA, Hidalgo M, Baker SD (2007) A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 846(1-2):1-7
26. Vergniol JC, Bruno R, Montay G, Frydman A (1992) Determination of taxotere in human plasma by a semi-automated highperformance liquid chromatographic method. J Chromatogr 582(1-2):273-278
27. Picus J, Schultz M (1999) Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 26:14-18
28. Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A (2010) Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562-4567
29. Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T (2012) Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors. Eur J Cancer 48:465-474
30. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P (2006) Lack of effect of ketokonazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 57:685-692
31. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302
32. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75:448-454
33. Flaherty KT, Redlinger M, Schuchter LM et al (2005) Phase I/II pharmacokinetic, pharmacodynamics trial of BAY 43-9006 alone in patients with metastatic melanoma. J Clin Oncol 23:201s (abstr 3037)
34. Mross K, Steinbild S, Baas F, Gmehling D, Radtke M, Voliotis D, Brendel E, Christensen O, Unger C (2007) Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 43:55-63
35. Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, Christensen O, Brendel E, Schwartz B, Ludwig M, Flashar C, Voigtmann R, Scheulen ME, Seeber S, Strumberg D (2006) Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 17:866-873
36. Azad NS, Aragon-Ching J, Dahut W et al (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15:1411-1416
37. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD, ASCENT (AIPC Study of Calcitriol ENhancing Taxotere) Investigators (2008) Intermittent chemotherapy in patients with metastatic androgenindependent prostate cancer: Results from ASCENT, a doubleblinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112:326-330
38. Galsky MD, Vogelzang NJ (2010) Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 21: 2135-2144
39. Kelly WK, Halabi S, Carducci MA et al (2010) A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 28:18s (abstr LBA4511)
40. Ou Y, Michaelson MD, Sengeløv L et al (2011) Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU ? P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 29:15s (abstr 4515)
41. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Maneval EC, Logothetis CJ (2012) Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A phase 1/2 clinical trial. Ann Oncol 23(3):688-694
42. Smith DC, Smith MR, Small EJ et al (2011) Phase II study of XL184 in a cohort of patients with castration-resistant prostate cancer and measurable soft tissue disease. J Clin Oncol 29(Suppl 7):S127
43. Cetnar JP, Rosen MA, Vaughn DJ et al (2009) Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer. J Clin Oncol 27 (15S) (abstr e16055)
44. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26:1148-1159